<DOC>
	<DOC>NCT02600559</DOC>
	<brief_summary>This is an 8-week, multicenter, open-label study in which eligible subjects with a history of otitis media requiring TT placement will receive 6 mg OTO-201 to each ear. The study is designed to evaluate the safety and efficacy of OTO-201 in subjects undergoing TT placement with common concurrent surgeries and any middle ear effusion status.</brief_summary>
	<brief_title>Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Inclusion Criteria includes, but is not limited to: Subject is a male or female aged 6 months to 17 years, inclusive Subject has a history of otitis media requiring bilateral tympanostomy tube placement Subject's caregiver is willing to comply with the protocol and attend all study visits Exclusion Criteria includes, but is not limited to: Subject has a history of prior ear or mastoid surgery, not including myringotomy or myringotomy with TT placement Subject has been designated for any other surgical procedure that would occur concurrently with TT placement, except adenoidectomy, airway endoscopy, nasal endoscopy, and nasal cautery for epistaxis Subject has a history of sensorineural hearing loss</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Otitis media</keyword>
	<keyword>Ear infection</keyword>
	<keyword>Tympanostomy tubes</keyword>
</DOC>